ArQule says Kyowa's ATTENTION deficit won't affect MARQUEE Phase III tivantinib study
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has stopped patient enrollment in the Phase III ATTENTION clinical trial in Asia for the ArQule cancer drug tivantinib due to cases of interstitial lung disease (ILD), but ArQule says the news will not impact its ongoing 1,000-patient Phase III MARQUEE trial conducted with Daiichi Sankyo in the Americas, Europe and other regions.